Track Harvard Bioscience, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Harvard Bioscience, Inc. HBIO Open Harvard Bioscience, Inc. in new tab

5.20 USD
EPS
-12.80
P/B
1.69
ROE
-147.13
Beta
1.50
Harvard Bioscience, Inc. logo

Harvard Bioscience, Inc.

🧾 Earnings Recap – Q3 2025

Harvard Bioscience achieved strong operational advancements in Q3 2025, reporting revenues of $20.6 million and improved margins, while demonstrating robust customer engagement and a growing backlog ahead of the fourth quarter.

  • Revenue of $20.6 million met guidance expectations, rebounding from a historically soft period.
  • Gross margin expanded to 58.4%, reflecting improved operational efficiency and a favorable product mix.
  • Customer order growth marked a year-over-year increase for the first time in over a year, driven by heightened demand and a growing product backlog.
  • Successful launch of the Incub8 Multiwell System bolstered market presence and initial customer feedback has been positive.
  • Strategic advances in capital structure highlight ongoing debt refinancing efforts, set for completion in Q4 2025.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateMay 11, 2026
EPS-12.80
Book Value3.07
Price to Book1.69
Debt/Equity322.39
% Insiders10.819%
Growth
Revenue Growth-0.03%
Estimates
Forward P/E6.50
Forward EPS0.80

DCF Valuation

Tweak assumptions to recompute fair value for Harvard Bioscience, Inc. (HBIO)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Harvard Bioscience, Inc. Logo Harvard Bioscience, Inc. Analysis (HBIO)

United States Health Care Official Website Stock

Is Harvard Bioscience, Inc. a good investment? Harvard Bioscience, Inc. (HBIO) is currently trading at 5.20 USD.

Earnings Schedule: Harvard Bioscience, Inc. is expected to release its next earnings report on May 11, 2026. The market consensus estimate for Forward EPS is 0.80.

Investor FAQ

Does Harvard Bioscience, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Harvard Bioscience, Inc.?

Harvard Bioscience, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be May 11, 2026. The company currently has a trailing EPS of -12.80.

Company Profile

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through websites and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic laboratories. It primarily sells its products under the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS, Warner, DSI, Panlab, Hugo Sachs, and Buxco brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

Exchange Ticker
NGM (Sweden) HBIO
FRA (Germany) HBI.F

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
Nov. 4, 2013 1.320000
March 16, 2026 0.100000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion